WO2006004545A1 - Reaction au tamoxifene chez des patientes presentant un cancer du sein pre-menopausique et post-menopausique - Google Patents

Reaction au tamoxifene chez des patientes presentant un cancer du sein pre-menopausique et post-menopausique Download PDF

Info

Publication number
WO2006004545A1
WO2006004545A1 PCT/SE2005/001116 SE2005001116W WO2006004545A1 WO 2006004545 A1 WO2006004545 A1 WO 2006004545A1 SE 2005001116 W SE2005001116 W SE 2005001116W WO 2006004545 A1 WO2006004545 A1 WO 2006004545A1
Authority
WO
WIPO (PCT)
Prior art keywords
dihydro
indol
oxo
methylidene
tamoxifen
Prior art date
Application number
PCT/SE2005/001116
Other languages
English (en)
Inventor
Göran LANDBERG
Lisa RYDÉN
Original Assignee
Forskarpatent I Syd Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forskarpatent I Syd Ab filed Critical Forskarpatent I Syd Ab
Priority to EP05757471A priority Critical patent/EP1773309A1/fr
Publication of WO2006004545A1 publication Critical patent/WO2006004545A1/fr
Priority to US11/620,275 priority patent/US20070213403A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation d'un inhibiteur du récepteur VEGFR2 dans la préparation d'une préparation pharmaceutique, pour améliorer la réaction à un traitement au tamoxifène, chez des patientes présentant un cancer du sein pré-ménopausique et post-ménopausique étant récepteur d'oestrogènes positives.
PCT/SE2005/001116 2004-07-07 2005-07-06 Reaction au tamoxifene chez des patientes presentant un cancer du sein pre-menopausique et post-menopausique WO2006004545A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05757471A EP1773309A1 (fr) 2004-07-07 2005-07-06 Reaction au tamoxifene chez des patientes presentant un cancer du sein pre-menopausique et post-menopausique
US11/620,275 US20070213403A1 (en) 2004-07-07 2007-01-05 Tamoxifen response in pre-and postmenopausal breast cancer patients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0401790A SE0401790D0 (sv) 2004-07-07 2004-07-07 Tamoxifen response in pre- and postmenopausal breast cancer patients
SE0401790-1 2004-09-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/620,275 Continuation US20070213403A1 (en) 2004-07-07 2007-01-05 Tamoxifen response in pre-and postmenopausal breast cancer patients

Publications (1)

Publication Number Publication Date
WO2006004545A1 true WO2006004545A1 (fr) 2006-01-12

Family

ID=32768801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2005/001116 WO2006004545A1 (fr) 2004-07-07 2005-07-06 Reaction au tamoxifene chez des patientes presentant un cancer du sein pre-menopausique et post-menopausique

Country Status (4)

Country Link
US (1) US20070213403A1 (fr)
EP (1) EP1773309A1 (fr)
SE (1) SE0401790D0 (fr)
WO (1) WO2006004545A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314887B2 (en) 2004-10-25 2008-01-01 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
US7662804B2 (en) 2004-05-28 2010-02-16 Smithkline Beecham Corp. Thrombopoietin activity modulating compounds and methods

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013152307A1 (fr) * 2012-04-05 2013-10-10 The Regents Of The University Of California Panneau d'expression génique pour le pronostic du cancer du sein

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034788A1 (fr) * 1998-12-08 2000-06-15 Board Of Regents, The University Of Texas System Procedes de detection du cancer du sein resistant aux anti-oestrogenes
WO2001027081A1 (fr) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma Kg Indolinones substituees en position 6, leur preparation et leur utilisation en tant que medicaments
WO2001060814A2 (fr) * 2000-02-15 2001-08-23 Sugen, Inc. Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
US6541504B1 (en) * 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
WO2003057690A1 (fr) * 2001-12-27 2003-07-17 Theravance, Inc. Derives d'indolinone utilises comme inhibiteurs de la proteine kinase
WO2003068229A1 (fr) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation N-oxydes de pyridine, de quinoline, et d'isoquinoline en tant qu'inhibiteurs de kinase
WO2004009601A1 (fr) * 2002-07-19 2004-01-29 Bristol-Myers Squibb Company Inhibiteurs de l'azaindole kinase
US6747025B1 (en) * 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
WO2004058234A2 (fr) * 2002-12-27 2004-07-15 Schering Aktiengesellschaft Nouvelle association pharmaceutique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539588A (en) * 1967-12-06 1970-11-10 American Home Prod Trans-1,4,4a,5,6,11b-hexahydro-11h-benzo(a) carbazol-5-one,thiosemicarbazones
US4769378A (en) * 1986-03-31 1988-09-06 Eli Lilly And Company Indenopyrimidine aromatase inhibitors
US6982142B2 (en) * 1997-12-01 2006-01-03 John Wayne Cancer Institute Methods for screening therapeutically effective agents
MXPA03003032A (es) * 2000-10-06 2003-06-06 Biomedicines Inc Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
US6951859B2 (en) * 2002-08-02 2005-10-04 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP1646382A4 (fr) * 2003-06-30 2010-07-21 Hif Bio Inc Composes, compositions et procedes
US7169802B2 (en) * 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034788A1 (fr) * 1998-12-08 2000-06-15 Board Of Regents, The University Of Texas System Procedes de detection du cancer du sein resistant aux anti-oestrogenes
WO2001027081A1 (fr) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma Kg Indolinones substituees en position 6, leur preparation et leur utilisation en tant que medicaments
WO2001060814A2 (fr) * 2000-02-15 2001-08-23 Sugen, Inc. Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
WO2003057690A1 (fr) * 2001-12-27 2003-07-17 Theravance, Inc. Derives d'indolinone utilises comme inhibiteurs de la proteine kinase
WO2003068229A1 (fr) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation N-oxydes de pyridine, de quinoline, et d'isoquinoline en tant qu'inhibiteurs de kinase
US6541504B1 (en) * 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
WO2004009601A1 (fr) * 2002-07-19 2004-01-29 Bristol-Myers Squibb Company Inhibiteurs de l'azaindole kinase
US6747025B1 (en) * 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
WO2004058234A2 (fr) * 2002-12-27 2004-07-15 Schering Aktiengesellschaft Nouvelle association pharmaceutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RYDEN L. ET AL: "Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow.up. Implication of a link between VEGF pathway and tamoxifen response", BREAST CANCER RESEARCH AND TREATMENT, vol. 89, no. 2, January 2005 (2005-01-01), pages 135 - 143, XP002992042 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662804B2 (en) 2004-05-28 2010-02-16 Smithkline Beecham Corp. Thrombopoietin activity modulating compounds and methods
US7314887B2 (en) 2004-10-25 2008-01-01 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
US7691895B2 (en) 2004-10-25 2010-04-06 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods

Also Published As

Publication number Publication date
US20070213403A1 (en) 2007-09-13
EP1773309A1 (fr) 2007-04-18
SE0401790D0 (sv) 2004-07-07

Similar Documents

Publication Publication Date Title
Nunnery et al. Targeting the PI3K/AKT/mTOR pathway in hormone-positive breast cancer
Larsen et al. Targeting EGFR and VEGF (R) pathway cross-talk in tumor survival and angiogenesis
Peters et al. MET: a promising anticancer therapeutic target
Goel et al. VEGF targets the tumour cell
Sakamoto et al. Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer
Akeno-Stuart et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells
Fereshteh et al. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice
Zhang et al. Targeting multiple signal transduction pathways through inhibition of Hsp90
Jin et al. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer
Garrett et al. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers
Johnson et al. Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy?
Chun et al. Predicting and overcoming chemotherapeutic resistance in breast cancer
Wargon et al. Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB 1 or SMRT recruitment to the CCND 1 and MYC promoters
Conceição et al. Sympathetic activity in breast cancer and metastasis: partners in crime
Zhou et al. Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells
Ma et al. Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells
Yin et al. Muscarinic acetylcholine receptor M1 mediates prostate cancer cell migration and invasion through hedgehog signaling
Yang et al. Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells
Crooke et al. Involvement of carbonic anhydrases in the ocular hypotensive effect of melatonin analogue 5‐MCA‐NAT
Zingg et al. Differential activation of the phosphatidylinositol 3′-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells
Li et al. Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model
Ocaña et al. The evolving landscape of protein kinases in breast cancer: clinical implications
Johnston et al. Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer
Ocana et al. Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options
US20070213403A1 (en) Tamoxifen response in pre-and postmenopausal breast cancer patients

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11620275

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005757471

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005757471

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11620275

Country of ref document: US